Drugs / NOV120401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02300467 | Dec 2014 → Jul 2016 | refractory malignant neoplasm | National OncoVenture | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOV120401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02300467 ↗ |
| Known as | CKD-516 Tablet | “The purpose of this open-label, dose-escalation phase I trial is to evaluate the safety, tolerability and pharmacokinetic profiles and to assess the efficacy of NOV120401...” NCT02300467 ↗ |